ClinicalTrials.gg
RecruitingNCT07096843PrisMNUpdated Oct 8, 2026

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

A Phase 2 interventional study of budoprutug in Primary Membranous Nephropathy, sponsored by Climb Bio, Inc.. Recruiting at 38 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Climb Bio, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Oct 8, 2026No longer in ChileSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Glomerulonephritis, Membranous with a site in China — 29 open to participants now, 37 under way, 10 of them phase 3. Glomerulonephritis, Membranous · China.

Planned enrollment
33rd of 50
45 · median 77
Started
2025
with 7 others
Phase 2
11 of 60
6 open now
Primary completion
2027-10
later than 23 of 36 live
Registered
47th of 60
by date

Among the 60 studies in Glomerulonephritis, Membranous with a site in China, this one is the 33rd largest by planned enrollment of the 50 interventional ones that give a count, is one of 8 that started in 2025, is one of 11 in phase 2, reaches primary completion later than 23 of the 36 other live ones, and was the 47th registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

29 of the 60 studies in Glomerulonephritis, Membranous with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Glomerulonephritis, Membranous with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN

Read the detailed description

Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity (ADCC). This Phase 2, open-label, multicenter study evaluates the safety, pharmacodynamics, and preliminary efficacy of three intravenous dose regimens of budoprutug in adult subjects with primary membranous nephropathy (PMN) who are anti-PLA2R antibody positive and have persistent proteinuria despite optimized RAAS inhibition. Approximately 45 subjects will be enrolled across three sequential dose cohorts, each receiving a single IV dose of budoprutug on Day 1, Day 15, Day 169 and Day 183. Subjects will be followed through Week 48, with extended follow-up for B-cell recovery as needed.

03

Conditions studied

  • Primary Membranous Nephropathy

Keywords

  • PMN
  • Anti-CD19
  • PrisMN
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of PMN with positive anti-PLA2R antibodies
  • CD19+ B cell count ≥40 cells/μL
  • UPCR ≥2.0 g/g
  • ≥35 mL/min/1.73 m²
  • Stable RAAS inhibitor therapy
  • Blood pressure \<150/90 mmHg at baseline
  • Adequate hematologic, hepatic, and renal function
  • Willing to use effective (both sexes)
  • Other inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Secondary Membranous Nephropathy
  • Rapidly progressive glomerulonephritis or other glomerulopathies
  • Prior B cell-depleting therapy within 24 weeks
  • Recent use of
  • Active or high-risk infections
  • History of
  • Pregnancy or breastfeeding
  • Recent major surgery or hospitalization
  • Other exclusion criteria may apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Dose Level A

    Drug: budoprutug

  • Experimental
    Cohort 2: Dose Level B

    Drug: budoprutug

  • Experimental
    Cohort 3: Dose Level C

    Drug: budoprutug

Interventions

  • Single IV dose of study product on Day 1, Day 15, Day 169 and Day 183

    Also known as: TNT119

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Number of participants experiencing TEAEs, graded per NCI CTCAE v5.0.

    Time frame: Up to Week 48

Secondary outcomes

  1. Change in total B Cell Count

    Absolute and % change in total number of peripheral B cells over time.

    Time frame: Up to Week 48

  2. Change in Anti-PLA2R Antibodies

    Change from Baseline in anti-PLA2R antibody titers over time.

    Time frame: Up to Week 48

  3. Complete Remission Rate

    Proportion of subjects who achieve complete remission at Week 48.

    Time frame: Week 48

  4. Complete or Partial Remission Rate

    Proportion of subjects who achieve complete or partial remission at Week 48.

    Time frame: Week 48

  5. Change in Proteinuria

    Change from Baseline in proteinuria (measured via urine protein-creatinine ratio, UPCR) over time.

    Time frame: Up to Week 48

  6. Change in UACR

    Change in urine albumin-to-creatinine ratio over time.

    Time frame: Up to Week 48

  7. Change in eGFR

    Change from Baseline in eGFR over time.

    Time frame: Up to Week 48

  8. Area Under the Curve (AUC)

    Measurement of the area under the drug concentration-time curve.

    Time frame: Up to Week 48

  9. Maximum Observed Plasma Concentration (Cmax)

    Measurement of the maximum observed plasma concentration.

    Time frame: Up to Week 48

  10. Time to Maximum Observed Concentration (Tmax)

    Measurement of the time to maximum observed concentration.

    Time frame: Up to Week 48

  11. Terminal Half-Life (T1/2)

    Measurement of the terminal half-life in days.

    Time frame: Up to Week 48

  12. Apparent Clearance (CL/F)

    Measurement of the apparent clearance in L/hour.

    Time frame: Up to Week 48

  13. Volume of Distribution (Vd)

    Measurement of the volume of distribution in liters.

    Time frame: Up to Week 48

07

Study locations

35 of 38 sites recruiting
  • Climb Bio Investigative Site #110
    Denver, Colorado 80220, United States
    Recruiting
  • Climb Bio Investigative Site #105
    Orlando, Florida 32086, United States
    Recruiting
  • Climb Bio Investigative Site #108
    Atlanta, Georgia 30342, United States
    Recruiting
  • Climb Bio Investigative Site #106
    Indianapolis, Indiana 46268, United States
    Recruiting
  • Climb Bio Investigative Site #101
    Clifton Park, New York 12065, United States
    Recruiting
  • Climb Bio Investigative Site #104
    Sherman, Texas 75092, United States
    Recruiting
  • Climb Bio Investigative Site# 602
    Buenos Aires, B1629, Argentina
    Recruiting
  • Climb Bio Investigative Site# 603
    Buenos Aires, B1888, Argentina
    Recruiting
  • Climb Bio Investigative Site #601
    CABA, C1111, Argentina
    Recruiting
  • Climb Bio Investigative Site #604
    CABA, C1425, Argentina
    Recruiting
  • Climb Bio Investigative Site #606
    Santa Fe, S3000, Argentina
    Recruiting
  • Climb Bio Investigative Site #502
    Belo Horizonte, 30150-320, Brazil
    Recruiting
  • Climb Bio Investigative Site #505
    Minas Gerais, 36010-570, Brazil
    Recruiting
  • Climb Bio Investigative Site #506
    Pernambuco, 50670-901, Brazil
    Recruiting
  • Climb Bio Investigative Site #501
    Porto Alegre, 90020-090, Brazil
    Recruiting
  • Climb Bio Investigative Site #503
    São Paulo, 05403-000, Brazil
    Recruiting
  • Climb Bio Investigative Site #504
    São Paulo, 05403-000, Brazil
    Recruiting
  • Climb Bio Investigative Site #403
    Beijing, Changping District 102218, China
    Not yet recruiting
  • Climb Bio Investigative Site #401
    Beijing, Cheng District 100034, China
    Recruiting
  • Climb Bio Investigative Site #408
    Shenzhen, Guangdong 518036, China
    Not yet recruiting
  • Climb Bio Investigative Site #402
    Wuxi, Jiangsu 214023, China
    Recruiting
  • Climb Bio Investigative Site #405
    Jinan, Shandong 250014, China
    Not yet recruiting
  • Climb Bio Investigative Site #409
    Yantai, Shandong 264000, China
    Recruiting
  • Climb Bio Investigative Site #404
    Yibin, Sichuan 644000, China
    Recruiting
  • Climb Bio Investigative Site #406
    Beijing, Xicheng District 100044, China
    Recruiting
  • Climb Bio Investigative Site #903
    Tbilisi, 0112, Georgia
    Recruiting
  • Climb Bio Investigative Site #902
    Tbilisi, 0114, Georgia
    Recruiting
  • Climb Bio Investigative Site #901
    Tbilisi, 0144, Georgia
    Recruiting
  • Climb Bio Investigative Site #204
    Taichung, 404, Taiwan
    Recruiting
  • Climb Bio Investigative Site# 202
    Taipei, 100, Taiwan
    Recruiting
  • Climb Bio Investigative Site# 201
    Taipei, 110, Taiwan
    Recruiting
  • Climb Bio Investigative Site #205
    Taipei, 112, Taiwan
    Recruiting
  • Climb Bio Investigative Site# 203
    Taipei, 235, Taiwan
    Recruiting
  • Climb Bio Investigative Site #803
    Ivano-Frankivsk, 76008, Ukraine
    Recruiting
  • Climb Bio Investigative Site# 801
    Kyiv, 02125, Ukraine
    Recruiting
  • Climb Bio Investigative Site #805
    Kyiv, 03151, Ukraine
    Recruiting
  • Climb Bio Investigative Site #804
    Rivne, 33027, Ukraine
    Recruiting
  • Climb Bio Investigative Site #802
    Ternopil, 46002, Ukraine
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Oct 2027, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Jul 31, 2025
StartActual
Aug 25, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites removed; no longer in Chile. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Climb Bio Investigative Site #409 · Yantai, ChinaNot yet recruiting→Recruiting
  • Climb Bio Investigative Site #404 · Yibin, ChinaNot yet recruiting→Recruiting
  • Climb Bio Investigative Site #406 · Beijing, ChinaNot yet recruiting→Recruiting
Show 5 removed
  • Climb Bio Investigative Site #111 · Boston, United States
  • Climb Bio Investigative Site #701 · Temuco, Chile
  • Climb Bio Investigative Site #703 · Valdivia, Chile
  • Climb Bio Investigative Site #702 · Santiago, Chile
  • Climb Bio Investigative Site #407 · Xi'an, China
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    5 sites removed; no longer in Chile. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Climb Bio Investigative Site #409 · Yantai, ChinaNot yet recruiting→Recruiting
    • Climb Bio Investigative Site #404 · Yibin, ChinaNot yet recruiting→Recruiting
    • Climb Bio Investigative Site #406 · Beijing, ChinaNot yet recruiting→Recruiting
    Show 5 removed
    • Climb Bio Investigative Site #111 · Boston, United States
    • Climb Bio Investigative Site #701 · Temuco, Chile
    • Climb Bio Investigative Site #703 · Valdivia, Chile
    • Climb Bio Investigative Site #702 · Santiago, Chile
    • Climb Bio Investigative Site #407 · Xi'an, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07096843
Lead sponsor
Climb Bio, Inc.
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Aug 25, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Climb Bio Study Director
Contact
clinicaltrials@climbbio.com
+1 866 857 2596

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budoprutug

Start the discussion